R&D channel feed – Endpoints News

R&D channel feed

On a journey to find and fuel new biotech ventures, Arix adds France's Ipsen to its network of partners

8 years ago

AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII

8 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

8 years ago

Takeda commits to a $230M package to seal blockbuster neurological R&D deal with Wave Life Sciences

8 years ago

AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones

8 years ago

Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide

8 years ago

AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight Alzheimer’s

8 years ago

Roche and Takeda try on Emulate’s 'organ chip' tech for R&D

8 years ago

Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact

8 years ago

FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market

8 years ago

Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis

8 years ago

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

8 years ago

Pfizer, Merck KGaA say their PD-L1 Bavencio also flunked PhIII in the all-important lung cancer field

8 years ago

Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus

8 years ago

CureVac to develop mRNA-based flu, malaria vaccines with new Gates Foundation grants

8 years ago

Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'

8 years ago

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

8 years ago

Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer's

8 years ago

Tetraphase’s second PhIII for its lead antibiotic fails in a repeat setback for UTIs

8 years ago

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

8 years ago

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

8 years ago

New year, new tax rates. How did the world’s biggest drugmakers fare?

8 years ago

What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

8 years ago

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

8 years ago

First page Previous page 277 278 279280281 282 283 Next page Last page